Immunome, Inc. (IMNM)
NASDAQ: IMNM · IEX Real-Time Price · USD
13.83
-0.57 (-3.96%)
At close: May 17, 2024, 4:00 PM
13.84
+0.01 (0.07%)
After-hours: May 17, 2024, 7:48 PM EDT
Immunome Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Immunome stock have an average target of 30.67, with a low estimate of 24 and a high estimate of 35. The average target predicts an increase of 121.76% from the current stock price of 13.83.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Immunome stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Initiates $24 | Buy | Initiates | $24 | +73.54% | Apr 30, 2024 |
| Guggenheim | Guggenheim | Strong Buy Initiates $35 | Strong Buy | Initiates | $35 | +153.07% | Apr 15, 2024 |
| Wedbush | Wedbush | Buy Maintains $27 → $33 | Buy | Maintains | $27 → $33 | +138.61% | Apr 1, 2024 |
| Wedbush | Wedbush | Buy Maintains $12 → $19 | Buy | Maintains | $12 → $19 | +37.38% | Jan 23, 2024 |
| Wedbush | Wedbush | Buy Initiates $12 | Buy | Initiates | $12 | -13.23% | Dec 19, 2023 |
Financial Forecast
Revenue This Year
5.44M
from 14.02M
Decreased by -61.19%
Revenue Next Year
n/a
from 5.44M
EPS This Year
-1.94
from -5.38
EPS Next Year
-2.41
from -1.94
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 16.8M | n/a | 27.9M | 161.2M | 353.9M |
| Avg | 5.4M | n/a | 10.4M | 75.2M | 159.3M |
| Low | n/a | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 19.8% | - | - | 1,455.0% | 370.5% |
| Avg | -61.2% | - | - | 625.5% | 111.8% |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.31 | -1.52 | -1.84 | -2.30 | -1.31 |
| Avg | -1.94 | -2.41 | -2.81 | -2.23 | -1.28 |
| Low | -2.23 | -3.05 | -3.28 | -2.15 | -1.23 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.